Pancreatic cancer cells continuously rewrite their own genetic code to dodge treatment and spread through the body, according to the most detailed single-cell analysis of the disease ever conducted — published October 13, 2026, in the journal Nature Genetics.
443,451 Cells, One Clear Pattern
Researchers at NYU Langone Health and its Perlmutter Cancer Center analyzed the genetic activity in 443,451 single cells taken from 62 tumors in 56 men and women with pancreatic ductal adenocarcinoma — one of the deadliest cancers, which kills nearly 85 percent of patients within five years of diagnosis. Six patients provided tumor samples both before and after chemotherapy.
The study was led by Despoina Kalfakakou, PhD, a postdoctoral research fellow at NYU Grossman School of Medicine, with co-senior investigator Aristotelis Tsirigos, PhD, and collaborators at Oregon Health and Science University and UC San Diego.
Unlike past research that analyzed tumor cells in bulk, the team examined cells individually — revealing a diverse set of "clones," clusters of tumor cells with similar genetic makeup that behave in strikingly different ways.
How the Cancer Outsmarts Treatment
Some clones evolved to resist therapy while others acquired the ability to spread rapidly. The findings finally explain a long-standing mystery: how cancer cells shift between the "classical" (less aggressive) and "basal" (more aggressive) subtypes of the disease. The team showed that ongoing genetic reconfiguration within a single tumor enables cells to transition between subtypes.
The study flagged specific genetic changes driving this evolution, including increased activity of the MYC gene in aggressive tumor cell populations. In lab experiments, blocking MYC activity reverted aggressive basal tumor cells to the less aggressive classical form and exposed them to more immune cells — potentially making them vulnerable to immune attack.
The clones also explained why pancreatic cancer resists immunotherapy: in some clones, the TIGIT gene was more active, producing proteins that help cancer evade immune detection, while activity of the PD1 gene was suppressed — which may explain why PD1-targeting immunotherapies rarely work against this cancer.
What It Means for Future Treatment
Clinical trials using MYC inhibitors or TIGIT inhibitors for pancreatic ductal carcinoma and other cancers are already underway, and the researchers say their findings should encourage larger investigations into different cancer cell states and how to target treatment toward each one.
The takeaway: by mapping how tumors evolve cell by cell, scientists now have the cancer's playbook — and a clearer map of where to strike next in one of oncology's hardest fights.
Watch: YouTube search results for pancreatic cancer research videos.
Music in this post's reel: Kevin MacLeod - Our Story Begins (incompetech.com), licensed under CC BY 3.0